Pirarubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pirarubicin
Accession Number
DB11616
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Adriamycin, tetrahydropyranyl
  • Theprubicin
  • THP-Adm
  • THP-Doxorubicin
Product Ingredients
IngredientUNIICASInChI Key
Pirarubicin hydrochlorideE7V83174BE95343-20-7ZPHYPKKFSHAVOE-YZIXBPQXSA-N
Categories
UNII
D58G680W0G
CAS number
72496-41-4
Weight
Average: 627.643
Monoisotopic: 627.231575635
Chemical Formula
C32H37NO12
InChI Key
KMSKQZKKOZQFFG-YXRRJAAWSA-N
InChI
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21+,22-,31+,32-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yloxy]oxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Pirarubicin.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Pirarubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Pirarubicin.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Pirarubicin.
ActeosideThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Acteoside.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pirarubicin.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Pirarubicin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pirarubicin.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pirarubicin.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Pirarubicin.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01885
PubChem Compound
11296583
PubChem Substance
347828009
ChemSpider
9471567
ChEBI
94770
ChEMBL
CHEMBL2354444
Wikipedia
Pirarubicin
ATC Codes
L01DB08 — Pirarubicin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingPreventionBladder Recurrence / Nephroureterectomy / Upper Tract Urothelial Carcinoma1
2RecruitingPreventionBladder Recurrence / Upper Tract Urothelial Carcinoma1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentIntravesical Instillation1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2, 3Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2, 3RecruitingTreatmentOverall Survival / Progression-free Survival / Toxicity1
3CompletedTreatmentNeoplasms, Breast1
3RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentCancer, Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.301 mg/mLALOGPS
logP2.06ALOGPS
logP2.05ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.99ChemAxon
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area204.3 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity157.38 m3·mol-1ChemAxon
Polarizability64.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthraquinones / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Oxanes / Monosaccharides
show 11 more
Substituents
Anthracycline / Anthracyclinone-skeleton / Aminoglycoside core / Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Glycosyl compound / O-glycosyl compound / Tetralin
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on August 25, 2016 16:58 / Updated on October 01, 2018 16:45